Inhibition of Foxo3 during myogenic differentiation

Introduction

Patients suffering from disease-related (secondary) sarcopenia have been associated with an enhanced level of the transcription factor Foxo3 in skeletal muscle [1] [2] [3].

Sarcopenia is a progressive and generalized muscle disorder characterized by a decline in muscle mass and strength [4]. If left untreated, it can lead to increased falls, fractures [5] [6], mortality [7], reduced quality of life [8], as well as increased hospitalization rates and cost of care [9].

Foxo3 is one of several transcription factors of the highly conserved Forkhead-Box-Protein family [10]. As a downstream target of the PI3K/AKT pathway [11], Foxo3 plays an important role in protein turnover and muscle wasting [12]. Foxo3 therefore could pose to be a potential target of treatment for secondary sarcopenia.

The focus of this study is to reduce the Foxo3-expression in murine myoblasts in vitro and to analyze changes in myogenic differentiation.

Publikationsverlauf

Artikel online veröffentlicht:
04. November 2021

• References

• 1 Kneppers et al. Journal of the American Medical Directors Association 2017 (18) 637.e1–637.e11
• 2 Mercken et al. Aging Cell 2013 (12), 645–651
• 3 Parolo et al. PLoS ONE 2018 (13), e0194225
• 4 Cruz-Jentoft et al. Age and Ageing 2019 (48), 16–31
• 5 Bischoff-Ferrari et al. Osteoporos Int 2015 (10), 10.1007/s00198-015-3194-y
• 6 Schaap et al. The Journals of Gerontology: Series A 2018 (73), 1199–1204
• 7 De Buyser et al. Age Ageing 2016 (45), 603–608
• 8 Rosenberg. J. Nutr. 1997 (127), 990S–991S
• 9 Cawthon et al. The Journals of Gerontology: Series A 2017 (72), 1383–1389
• 10 Hannenhalli et al. Nat Rev Genet 2009 (10), 233–240
• 11 Brunet et al. Cell 1999 (96), 857–868
• 12 Sacheck et al. American Journal of Physiology-Endocrinology and Metabolism 2004 287, E591–E601